News Sentiment

CRSP sentiment intelligence

Crispr Therapeutics AG news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 53.35 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-11.2% over one week, +7.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

CRISPR Therapeutics Stock 6-Day Losing Spree: Stock Falls 18%

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -11.2% Price reacting lower
Trend fit Trend inactive 7.1% over four weeks
Fair value 0.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 38
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
TradingView 11
The Motley Fool 4
Ad-hoc-news.de 4
MarketBeat 3
Trefis 2
Moomoo 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 18
Analyst action 5
Guidance 2
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
MarketBeat Direct company coverage

Canal Insurance CO Purchases New Stake in CRISPR Therapeutics AG $CRSP

Canal Insurance CO has acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, purchasing 35,100 shares valued at approximately $1.67 million. Institutional investors and hedge funds now own 69.20% of the company's stock, with several firms increasi

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 08:42
Source
MarketBeat
MarketBeat Direct company coverage

CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in CRISPR Therapeutics AG ($CRSP) by 5.3% in the first quarter of 2026, selling over 104,000 shares to hold 1.85 million shares valued at approximately $88.2 million. Despite this reduction and the company reporting a Q1 EPS of -

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 14:41
Source
MarketBeat
Market source Direct company coverage

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

CRISPR Therapeutics AG (CRSP) saw its stock dip by 5.31% while the broader market gained. Despite the recent dip, the company's shares have appreciated by 12.16% over the past month, outperforming its sector and the S&P 500. Analysts anticipate significant year-over-year growth i

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:50
Source
Market source
The Globe and Mail Direct company coverage

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Crispr Therapeutics AG (CRSP) with an $83 price target. This follows a similar Buy rating by Piper Sandler. The company reported a quarterly revenue of $1.46 million and a GAAP net loss of $122.93 milli

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 00:45
Source
The Globe and Mail
Market source Direct company coverage

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

This article compares CRISPR Therapeutics and Viking Therapeutics, two biotechnology companies with different focuses: gene-editing and weight loss. While CRISPR Therapeutics has already launched its gene therapy Casgevy, Viking Therapeutics is a clinical-stage company with no cu

Tone
Positive 60/100
Event
Market update
Published
08 Jul 2026 00:45
Source
Market source
Finviz Direct company coverage

CRSP - CRISPR Therapeutics AG Options

This article provides detailed financial and stock option data for CRISPR Therapeutics AG (CRSP). It includes key metrics such as market cap, income, sales, EPS, various performance indicators, and insider/institutional ownership percentages, alongside recent trading performance

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 16:39
Source
Finviz
Investing.com Direct company coverage

Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential

Citizens maintained a Market Outperform rating and an $80.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) shares, noting the company's stock is currently trading at $60.08, up 6.6% over the past week. The firm believes the expansion of the CASGEVY label to patients aged 2 or

Tone
Positive 70/100
Event
Analyst action
Published
06 Jul 2026 10:13
Source
Investing.com
Simply Wall Street Direct company coverage

Does CRISPR Therapeutics’ (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative?

CRISPR Therapeutics (CRSP) was recently added to several Russell growth indexes, increasing its visibility to growth-focused investors and potentially influencing its investment narrative. While this inclusion may boost liquidity and market reactions, it doesn't fundamentally alt

Tone
Neutral 50/100
Event
Balance sheet
Published
05 Jul 2026 21:13
Source
Simply Wall Street
FXEmpire Direct company coverage

CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices

CRISPR Therapeutics (CRSP) stock has experienced a significant breakout from a multi-week consolidation, confirmed by strong trading volume. This breakout from dual inverse head and shoulders patterns suggests a bullish reversal and potential for higher prices, with measured targ

Tone
Positive 75/100
Event
Guidance
Published
03 Jul 2026 21:05
Source
FXEmpire
Market source Direct company coverage

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

The article discusses why CRISPR Therapeutics AG (CRSP) is a heavily searched stock, focusing on its earnings estimates, revenue growth, and valuation. CRSP has outperformed the S&P 500 and its industry recently, but its Zacks Rank is a #3 (Hold) due to recent estimate changes an

Tone
Positive 65/100
Event
Earnings
Published
30 Jun 2026 13:09
Source
Market source
TradingView Direct company coverage

ETFs Investing in CRISPR Therapeutics AG Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of CRISPR Therapeutics AG (0VRQ). The list, sorted by market value, provides details such as the percentage weight of CRISPR in the ETF, the issuer, management style, focus, expense ratio, assets under manag

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 11:39
Source
TradingView
marketscreener.com Direct company coverage

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Growth Benchmark

CRISPR Therapeutics AG (NasdaqGM:CRSP), a gene-editing company, has been added to the Russell 2000 Growth Benchmark. The company's stock is currently trading at $56.35, with a positive year-to-date change. This inclusion is among several recent additions to various Russell benchm

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 09:41
Source
marketscreener.com
marketscreener.com Direct company coverage

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000E Growth Benchmark

CRISPR Therapeutics AG (NasdaqGM: CRSP) has been added to the Russell 3000E Growth Benchmark. The company, a Switzerland-based gene editing firm, focuses on developing CRISPR/Cas9-based therapeutics to treat genetically defined diseases and engineer advanced cellular therapies. T

Tone
Positive 69/100
Event
Regulatory and legal
Published
29 Jun 2026 04:39
Source
marketscreener.com
Sahm Direct company coverage

What CRISPR Therapeutics (CRSP)'s Upgraded Revenue and EPS Forecasts Mean For Shareholders

Analysts have recently raised revenue and EPS forecasts for CRISPR Therapeutics, suggesting increased confidence in the company's near-term gene-editing revenue potential, partly due to its partnership with Vertex. While this optimism could sharpen near-term catalysts, investors

Tone
Positive 68/100
Event
Earnings
Published
28 Jun 2026 10:40
Source
Sahm
TradingView Direct company coverage

Price to sales forward of CRISPR Therapeutics AG – DUS:1CG

This article provides the "Price to sales forward" metric for CRISPR Therapeutics AG (DUS:1CG). The financial data is sourced from ICE Data Services and FactSet Research Systems Inc., with SEC filings provided by Quartr. The specific value for this metric is not detailed in the p

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of CRISPR Therapeutics AG – NASDAQ:CRSP

This article provides a brief overview of CRISPR Therapeutics AG (NASDAQ: CRSP) focusing on its price to sales forward metric. It also lists various financial and community features available on the TradingView platform for this stock. The content indicates that the market is cur

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 16:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of CRISPR Therapeutics AG – NASDAQ:CRSP

This article provides financial data specifically regarding the Enterprise Value to EBIT forward ratio for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication and presents a table showing the period, value, change, and percent

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 10:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of CRISPR Therapeutics AG – NASDAQ:CRSP

This article headline indicates a financial analysis for CRISPR Therapeutics AG (NASDAQ:CRSP), specifically focusing on its enterprise value to forward revenue ratio. The content appears to be a stub or an indication of where such financial data would be presented on the TradingV

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 09:40
Source
TradingView